T-cell replete cord vs comparator cohort cGFRFS. (A) cGFRFS was significantly improved for MRD-positive recipients of a T-replete cord compared with other transplant type, 48% (95% CI, 32-62) vs 11% (95% CI, 5-21) (HR 0.44 [95% CI, 0.28-0.71]; P = .001). (B) In MRD-negative patients, cGFRFS was 67% (95% CI, 51-79) and 56% (95% CI, 48-64) for TRCB and comparator transplant recipients respectively, (HR, 0.75 [95% CI, 0.43-1.3]; P = .30), P value for interaction = .17. cGFRFS, chronic GvHD-free relapse-free survival.